CYCLERION THERAPEUTICS, INC. Income (Loss) from Continuing Operations, Per Diluted Share
CYCLERION THERAPEUTICS, INC. (CYCN) reported Income (Loss) from Continuing Operations, Per Diluted Share of -$1.21 per share for the 12-month period ending 2024-12-31, per its 10-K/A filed 2025-11-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2025-11-12
- CYCLERION THERAPEUTICS, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2024-09-30 was -$0.29.
- CYCLERION THERAPEUTICS, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2024-06-30 was -$0.53.
- CYCLERION THERAPEUTICS, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2024-03-31 was -$0.62.
- CYCLERION THERAPEUTICS, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2023-09-30 was -$2.12.
- CYCLERION THERAPEUTICS, INC. income (loss) from continuing operations, per diluted share for fiscal 2024 was -$1.21.
- CYCLERION THERAPEUTICS, INC. income (loss) from continuing operations, per diluted share for fiscal 2023 was -$5.39.
- CYCLERION THERAPEUTICS, INC. income (loss) from continuing operations, per diluted share for fiscal 2022 was -$8.40.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$1.21 10-K/A · filed 2025-11-12 | |||
| 2024-09-30 | -$0.29 10-Q · filed 2024-11-14 | -$1.43 10-Q · filed 2024-11-14 | ||
| 2024-06-30 | -$0.53 10-Q · filed 2024-08-07 | -$1.14 10-Q · filed 2024-08-07 | ||
| 2024-03-31 | -$0.62 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | -$5.39 10-K/A · filed 2025-11-12 | |||
| 2023-09-30 | -$2.12 10-Q · filed 2024-11-14 | -$4.74 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | -$0.79 10-Q · filed 2024-08-07 | -$2.24 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | -$1.46 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | -$8.40 10-K · filed 2024-03-05 | |||
| 2022-09-30 | -$2.03 10-Q · filed 2023-11-13 | -$6.41 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |